You have 9 free searches left this month | for more free features.

BTC

Showing 1 - 25 of 240

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Biliary Cancer, Bile Duct Cancer, Cancer of the Bile Duct Trial run by the National Cancer Institute (NCI) (oxaliplatin,

Not yet recruiting
  • Biliary Cancer
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
May 13, 2023

Chronic Constipation Trial in Wonju (Electrolyzed Alkaline Ionizer)

Completed
  • Chronic Constipation
  • Electrolyzed Alkaline Ionizer
  • Wonju, Ganwon-do, Korea, Republic of
    Wonju College of Medicine
Feb 8, 2023

Biliary Tract Tumors Trial (Total Neoadjuvant Treatment)

Not yet recruiting
  • Biliary Tract Neoplasms
  • Total Neoadjuvant Treatment
  • (no location specified)
Sep 7, 2023

Imfinzi BTC Japan PMS_Japan Post-Marketing Surveillance Study -

Not yet recruiting
  • Biliary Tract Cancer
    • (no location specified)
    Apr 26, 2023

    Incidental Gallbladder Carcinoma-Permanent Platform Including

    Recruiting
    • Biliary Tract Cancer
    • Neoadjuvant, Adjuvant and 1st Line
      • Frankfurt, Germany
        Krankenhaus Nordwest GmbH
      Aug 3, 2022

      Intrahepatic Cholangiocarcinoma Trial in Shanghai (GP+PD-1+Tight)

      Withdrawn
      • Intrahepatic Cholangiocarcinoma
      • Shanghai, Shanghai, China
        Zhongshan hospital, Fudan University
      Mar 22, 2022

      Biliary Tract Carcinoma Trial in Beijing (Gemcitabine, S1, Tislelizumab)

      Not yet recruiting
      • Biliary Tract Carcinoma
      • Beijing, China
        Chinese Academy of Medical Sciences & Peking Union Medical Colle
      Apr 10, 2023

      Biliary Tract Carcinoma Trial in Shanghai (GP+PD-1+Tight)

      Recruiting
      • Biliary Tract Carcinoma
      • Shanghai, China
        Zhongshan hospital
      Mar 22, 2022

      Biliary Tract Cancer, Immune Checkpoint Inhibitor, Predictive Cancer Model Trial in Beijing (Immune Checkpoint Inhibitors)

      Recruiting
      • Biliary Tract Cancer
      • +2 more
      • Immune Checkpoint Inhibitors
      • Beijing, Beijing, China
        Chinese Academy of Medical Sciences & Peking Union Medical Colle
      Oct 5, 2023

      Advanced Biliary Tract Cancer Trial in Changsha (IBI310, sintilimab)

      Not yet recruiting
      • Advanced Biliary Tract Cancer
      • Changsha, Hunan, China
        Hunan cancer Hospital
      Dec 13, 2022

      Advanced Primary Liver Cancer, Advanced Biliary Tract Carcinoma Trial in Zhengzhou, Nanjing (SHR-1210, Apatinib, FOLFOX4)

      Active, not recruiting
      • Advanced Primary Liver Cancer
      • Advanced Biliary Tract Carcinoma
      • SHR-1210
      • +3 more
      • Zhengzhou, Henan, China
      • +1 more
      Apr 26, 2022

      Biliary Tract Cancer, Cholangiocarcinoma Trial in Italy (Gemcitabine, Nab paclitaxel, Cisplatin)

      Not yet recruiting
      • Biliary Tract Cancer
      • Cholangiocarcinoma
      • Ancona, Italy
      • +18 more
      Sep 16, 2023

      Incidental Gallbladder Carcinoma, Biliary Tract Cancer Trial in Frankfurt (Gemcitabine, Cisplatin, Oncologically radical

      Recruiting
      • Incidental Gallbladder Carcinoma
      • Biliary Tract Cancer
      • Frankfurt, Germany
        Krankenhaus Nordwest gGmbH
      Sep 7, 2022

      Biliary Tract Cancers Trial (durvalumab)

      Not yet recruiting
      • Biliary Tract Cancers
      • (no location specified)
      Jun 20, 2023

      Biliary Tract Carcinoma, Cholangiocarcinoma, Bile Duct Cancer Trial in Madison (Gemcitabine, Cisplatin, Zimberelimab)

      Not yet recruiting
      • Biliary Tract Carcinoma
      • +2 more
      • Madison, Wisconsin
        University of Wisconsin
      Sep 15, 2023

      AssesSment of Early-deteCtion basEd oN liquiD Biopsy in Biliary

      Recruiting
      • Biliary Tract Cancer
      • Blood drawing
      • Guangzhou, Guangdong, China
      • +1 more
      Dec 28, 2022

      Intrahepatic Cholangiocarcinoma Trial in Germany (Durvalumab, Tremelimumab)

      Recruiting
      • Intrahepatic Cholangiocarcinoma
      • Dresden, Germany
      • +7 more
      Apr 13, 2022

      Biliary Tract Tumors, Liver Cancer, Hepatocellular Carcinoma Trial run by the NCI (Durvalumab, Tremelimumab, Trans-arterial

      Active, not recruiting
      • Biliary Tract Neoplasms
      • +4 more
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      Mar 1, 2022

      Locally Advanced Biliary Tract Cancer, Metastatic Biliary Tract Cancer Trial in Guangzhou (Camrelizumab and Apatinib Plus GP)

      Not yet recruiting
      • Locally Advanced Biliary Tract Cancer
      • Metastatic Biliary Tract Cancer
      • Camrelizumab and Apatinib Plus GP
      • Guangzhou, Guangdong, China
        Cancer center of SunYat-sen University
      Feb 15, 2023

      Biliary Tract Adenocarcinoma Trial in Shanghai (HAIC, Gemcitabine, Oxaliplatin)

      Enrolling by invitation
      • Biliary Tract Adenocarcinoma
      • HAIC
      • +4 more
      • Shanghai, China
        Fudan University Shanghai Cancer Center
      May 27, 2022

      Biliary Tract Cancer Trial in Seoul (Pemetrexed 500 MG, Erlotinib)

      Recruiting
      • Biliary Tract Cancer
      • Seoul, Korea, Republic of
      • +1 more
      Jun 13, 2022

      Advanced Biliary Tract Cancer Trial in Guangzhou (Envofolimab, Lenvatinib, Gemcitabine)

      Recruiting
      • Advanced Biliary Tract Cancer
      • Guangzhou, Guangdong, China
        The First Affiliated Hospital of Sun Yat-sen University
      Oct 11, 2022

      Biliary Tract Tumors, Cholangiocarcinoma, Bile Duct Cancer Trial run by the NCI (Pembrolizumab (MK-3475), Oxaliplatin,

      Completed
      • Biliary Tract Neoplasms
      • +4 more
      • Pembrolizumab (MK-3475)
      • +2 more
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      Dec 1, 2021

      Hepatocellular Cancer, Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma Trial run by the NCI (durvalumab,

      Recruiting
      • Hepatocellular Cancer
      • +2 more
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      Jan 20, 2023

      Biliary Tract Cancer Trial in Shanghai (Capecitabine combined with lenvatinib and tislelizumab)

      Recruiting
      • Biliary Tract Cancer
      • Capecitabine combined with lenvatinib and tislelizumab
      • Shanghai, China
        Fudan University Shanghai Cancer Center
      Mar 23, 2022